Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma.
Desilets A, Vos JL, Katabi N, Kuo F, Nadeem Z, Linxweiler M, Ostrovnaya I, Baxi S, Dunn LA, Sherman EJ, Pfister DG, Morris LGT, Ho AL. Desilets A, et al. Among authors: ostrovnaya i. Clin Cancer Res. 2024 Dec 2;30(23):5281-5292. doi: 10.1158/1078-0432.CCR-24-1064. Clin Cancer Res. 2024. PMID: 39352719 Clinical Trial.
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Balar AV, et al. Among authors: ostrovnaya i. J Clin Oncol. 2013 Feb 20;31(6):724-30. doi: 10.1200/JCO.2012.42.5215. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341513 Free PMC article. Clinical Trial.
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ; ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators. Hakimi AA, et al. Among authors: ostrovnaya i. Clin Cancer Res. 2013 Jun 15;19(12):3259-67. doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25. Clin Cancer Res. 2013. PMID: 23620406 Free PMC article.
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE. Teo MY, et al. Among authors: ostrovnaya i. Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30. Clin Cancer Res. 2017. PMID: 28137924 Free PMC article.
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.
Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ. Voss MH, et al. Among authors: ostrovnaya i. Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327302 Clinical Trial.
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB. Audenet F, et al. Among authors: ostrovnaya i. Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23. Clin Cancer Res. 2019. PMID: 30352907 Free PMC article.
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.
Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, Li MO, Chan TA, Motzer RJ. Hakimi AA, et al. Among authors: ostrovnaya i. Cancer Discov. 2019 Apr;9(4):510-525. doi: 10.1158/2159-8290.CD-18-0957. Epub 2019 Jan 8. Cancer Discov. 2019. PMID: 30622105 Free PMC article. Clinical Trial.
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, Mano R, Coleman J, Russo P, Liu CH, Dannenberg AJ, Chan TA, Motzer R, Voss MH, Hakimi AA. Sanchez A, et al. Among authors: ostrovnaya i. Lancet Oncol. 2020 Feb;21(2):283-293. doi: 10.1016/S1470-2045(19)30797-1. Epub 2019 Dec 20. Lancet Oncol. 2020. PMID: 31870811 Free PMC article.
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V, Reardon B, Bhayankara A, Scott SN, Boyd ME, Garcia-Grossman IR, Regazzi AM, McCoy AS, Kim PH, Al-Ahmadie H, Ostrovnaya I, Roth AJ, Farooki A, Berger MF, Rosenberg JE, Solit DB, Van Allen E, Milowsky MI, Bajorin DF, Iyer G. McPherson V, et al. Among authors: ostrovnaya i. Cancer. 2020 Oct 15;126(20):4532-4544. doi: 10.1002/cncr.33071. Epub 2020 Aug 7. Cancer. 2020. PMID: 32767682 Free PMC article. Clinical Trial.
128 results